COSA 2021: After 5 Years, Encorafenib + Binimetinib Continues to Improve OS in BRAF V600-Mutant Melanoma
The combination outperforms vemurafenib or encorafenib alone.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.